The application delivers information capture, with customizable fields for ADE, study topic demographics, and illness information. Credit: National Cancer Institute for Unsplash.

BioVakis Technologies has acquired clinical trial management organization TAETSoftware (TAETCo), which develops and commercializes the Trial Adverse Events Tracker (TAET) technologies platform.

TAET is a computer software application that permits clinical study subjects to record and report clinical trial adverse events (ADEs) to trial sponsors in true time.

It is made to boost monitoring of adverse events and/or side effects in participants enrolled in clinical trials.

The app delivers study participants with a safe and private connection to quickly update investigators on any adverse events they expertise.

Facts can be updated in an on the internet database for true-time assessment by trial investigators.

TAET delivers a higher level of information capture, with customizable fields for ADE, study topic demographics and illness information, as properly as other study-connected variables.

This permits study participants and investigators to direct messages to each and every other if needed.

BioVakis Technologies CEO James Pasin mentioned: “The acquisition of TAETCo delivers BioVakis with a third, low-threat solution that generates close to-term income, supporting our core organization of building cancer and viral vaccines.”

“In addition to offering a charge-primarily based solution for recording ADE clinical research to CROs and study sponsors, BioVakis will seek to leverage current advances in artificial intelligence by collaborating with one particular or extra players in wellness information investigation to create insights into correlations in between demographics and other aspects and ADE.”

Beneath the terms of the agreement, the organization issued 24.five million popular shares to TAETCo shareholders, along with an added two.five million popular shares payable just after beta testing of the application.

BioVakis Technologies plans to discover the possible of providing blinded demographic and illness information to firms interested in healthcare analytics and information mining.

By Editor